期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 206, 期 10, 页码 2067-2077出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20090545
关键词
-
资金
- Institut National de la Sante et de la Recherche Medicale
- European Vascular Genomics Network
- Fund of Scientific Medical Research
- Belgian Federal Service for Scientific Technical and Cultural Affair
- Ministry of Education, Culture, Sports, Science, and Technology of Japan
- Program for Promotion of Fundamental Studies in Health Sciences
- National Institute of Biomedical Innovation
- Assistance Publique-Hopitaux de Paris
Atherosclerosis is an inflammatory vascular disease responsible for the first cause of mortality worldwide. Recent studies have clearly highlighted the critical role of the immuno-inflammatory balance in the modulation of disease development and progression. However, the immunoregulatory pathways that control atherosclerosis remain largely unknown. We show that loss of suppressor of cytokine signaling (SOCS) 3 in T cells increases both interleukin (IL)-17 and IL-10 production, induces an antiinflammatory macrophage phenotype, and leads to unexpected IL-17-dependent reduction in lesion development and vascular inflammation. In vivo administration of IL-17 reduces endothelial vascular cell adhesion molecule-1 expression and vascular T cell infiltration, and significantly limits atherosclerotic lesion development. In contrast, overexpression of SOCS3 in T cells reduces IL-17 and accelerates atherosclerosis. We also show that in human lesions, increased levels of signal transducer and activator of transcription (STAT) 3 phosphorylation and IL-17 are associated with a stable plaque phenotype. These results identify novel SOCS3-controlled IL-17 regulatory pathways in atherosclerosis and may have important implications for the understanding of the increased susceptibility to vascular inflammation in patients with dominant- negative STAT3 mutations and defective Th17 cell differentiation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据